Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2/3 Study for the Evaluation of Safety and Efficacy of Humacyte's ATEV for Vascular Replacement or Reconstruction in Patients With Life or Limb-threatening Vascular Trauma

NCT03005418 is registered in ClinicalTrials.gov with Humacyte, Inc. as lead sponsor.

NCT NCT03005418
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03005418 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2/3 Study for the Evaluation of Safety and Efficacy of Humacyte's ATEV for Vascular Replacement or Reconstruction in Patients With Life or Limb-threatening Vascular Trauma
Lead sponsor
Humacyte, Inc.
Phase
Phase 2/3
Overall status
Completed
Start date
September 1, 2018
Completion date
May 15, 2026
Enrollment
72 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

trauma, vascular system injury